Scientific deep-dive

Fat-to-Muscle Ratio: Surgery Versus Drugs

The lean-to-fat ratio improved in both groups at 6, 12 and 24 months. Everyone loses lean tissue when losing weight. The question is the mix, and both interventions improved it.

By Nora Bissett · Pricing Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

Arguments about muscle loss almost always use the wrong unit. What matters is not how much lean tissue you lose but the mix — how much lean comes off relative to fat. A cohort study measured exactly that after bariatric surgery and after semaglutide or tirzepatide, and the ratio improved in both groups at every time point.[1]

The numbers

Fat-free mass to fat mass ratio. Higher is a more favorable body composition.
Time pointBariatric surgeryGLP-1 receptor agonists
6 months1.81.4
12 months2.11.5
24 months2.01.5

Both groups lost substantial fat mass and moderate fat-free mass, and both improved the ratio between them. Surgery maintained a higher ratio throughout.[1]

The improving ratio is the finding people miss. Losing lean tissue while losing weight sounds like damage, and in isolation it looks like it. But if fat falls faster than lean, the body you end up with is proportionally more muscular than the one you started with, which is the opposite of wasting. Both interventions did that.

Why the comparison between columns is the weak part

This is a single-center cohort study, not a randomized comparison, and people who have bariatric surgery differ enormously from people prescribed a GLP-1 — in starting weight, in how long they have been trying, in what else has failed, and in the post-operative nutrition and follow-up programs that surgery carries with it.

Surgical patients also receive structured protein and supplementation protocols as standard care, which is precisely the intervention shown to preserve lean mass elsewhere. Some of that column difference may be the aftercare rather than the procedure. We cover the broader comparison, and its own methodological problems, in surgery versus GLP-1 drugs.

That both ratios improved is the robust finding. That one column is higher than the other is the fragile one.

The sex difference runs the other way

One stratified result deserves separating out, because it points opposite to a better-known finding. Men preserved fat-free mass better than women, especially after GLP-1 treatment.[1]

Meanwhile, women lose a larger percentage of body weight on these drugs — 10.9% against 6.8% in a review of 64 trials, covered in who loses more weight. Those are not contradictory. They are two different questions: how much total weight comes off, and what it is made of. Merging them would produce a wrong answer in either direction.

The practical implication falls on the same advice regardless: resistance training and adequate protein, which is the only intervention with randomized support for changing the mix. Our lean mass article has the figures, and protein targets has the numbers.

Frequently Asked Questions

No. In this cohort the fat-free mass to fat mass ratio improved on these drugs at 6, 12 and 24 months. Lean tissue was lost, but fat was lost faster, leaving a proportionally more muscular body than at the start.
Surgical patients maintained a higher ratio throughout in this study, but it is a single-center cohort rather than a randomized comparison, and surgery comes with structured protein and supplementation aftercare that is itself the intervention known to preserve lean mass. The column difference is the fragile part of the finding.
Because everyone loses some lean tissue when they lose weight, so the absolute figure always looks alarming. The ratio tells you whether fat came off faster than lean, which is what determines the body you end up with.
In this study men preserved fat-free mass better, especially after GLP-1 treatment. That sits alongside a separate finding that women lose a larger percentage of total body weight. They are different questions — how much comes off, and what it is made of.
Resistance training with adequate protein. It is the only intervention with randomized support for shifting the proportion of weight lost as lean mass, and it applies whichever route the weight loss came from.

References

  1. 1.Wang Z, Wang L, Zhang X, et al. Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists JAMA Network Open. 2026. PMID: 41511769.

Surgery Versus GLP-1 Drugs: Reading an Indirect Comparison

A network meta-analysis of 30 trials put surgery about 10 points ahead on total weight loss. Nobody was randomized to surgery versus a drug, and against tirzepatide alone the difference vanished.

6 min read

The Day the Balloon Comes Out

An intragastric balloon is removed on a scheduled date, which makes it an unusually clean experiment in what happens when a weight intervention ends. One group began regaining. The other kept losing.

6 min read

The Group That Lost Least Did Best

A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.

6 min read

The Line Is Drawn by Surgery

A meta-regression found study arms with greater average weight loss had higher rates of fatty liver disease resolving. The authors say plainly it cannot establish cause, and a handful of surgical arms are pulling the line.

6 min read

The Weight Comparison Used 257 People

A 30,458-patient study reported surgery producing 28.3% weight loss against 10.3% on GLP-1s, at lower two-year cost. The cost half uses the whole cohort. The weight half uses 1.6% of one arm.

7 min read

When Is It Safe to Have the Skin Removed?

Large weight loss leaves skin that does not retract. A review of 12 studies puts the weight plateau at 53 weeks, and the more consequential finding is about what happens if you stop the drug afterward.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

Direct Meds

Compounded semaglutide at $249/month

7.4

MEDGm

Month-to-month compounded semaglutide at $179 with the partner pharmacies named

5.7

HumeCare+

An oral route if you will not self-inject